TABLE 1.
Characteristic | Dose-Escalation Phase Total N = 55 |
---|---|
Sex | |
Male, no. (%) | 30 (55) |
Female, no. (%) | 25 (45) |
Race, no. (%) | |
White | 36 (65) |
Black/African American | 14 (25) |
Other | 5 (9) |
Median age (range), y | 63 (31–79) |
Median y since diagnosis (range) | 5.1 (1.5–12.0) |
Ig subtype at diagnosis, no. (%) | |
IgG | 34 (62) |
IgA | 9 (16) |
IgM | 1 (2) |
Light chain only | 11 (20) |
Light chain at diagnosis, no. (%) | |
Kappa | 34 (62) |
Lambda | 21 (38) |
ISS stage at diagnosis, no. (%) | |
I | 9 (16) |
II | 16 (29) |
III | 12 (22) |
Missing | 18 (33) |
ECOG performance status, no. (%) | |
0 | 19 (35) |
1 | 36 (65) |
Creatinine clearance, mL/minute | |
>90 | 24 (44) |
60–89 | 17 (31) |
30–59 | 13 (24) |
15–29 | 1 (2) |
High-risk cytogenetics, no. (%)a | |
Yes | 12 (22) |
No | 41 (75) |
Missing/unknown | 2 (4) |
Prior lines of therapy, median (range) | 3 (1–9) |
Prior proteasome inhibitor | 55 (100) |
Recurrent | 23 (42) |
Refractory | 31 (56) |
Unknown | 1 (2) |
Prior bortezomib | 52 (95) |
Recurrent | 23 (42) |
Refractory | 28 (51) |
Unknown | 1 (2) |
Prior carfilzomib | 9 (16) |
Refractory | 9 (16) |
Prior IMiD | 55 (100) |
Recurrent | 12 (22) |
Refractory | 42 (76) |
Prior lenalidomide | 54 (98) |
Recurrent | 12 (22) |
Refractory | 41 (75) |
Unknown | 1 (2) |
Prior pomalidomide | 7 (13) |
Refractory | 7 (13) |
Prior corticosteroid | 55 (100) |
Prior alkylator | 51 (93) |
Prior stem cell transplantation | 49 (89) |
Prior anthracycline | 22 (40) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; IMiD, immunomodulatory agent; ISS, International Staging System.
Defined as ≥1of the following: del(17p), t(14;16), or 1q21 gain.